[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] CAO W,CHEN H D,YU Y W,et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chin Med J(Engl),2021,134(7):783-791.
[3] CHECHLINSKA M,KOWALEWSKA M,NOWAK R.Systemic inflammation as a confounding factor in cancer biomarker discovery and validation[J].Nat Rev Cancer,2010,10(1):2-3.
[4] ZHANG K,PING L,OU X,et al.A systemic inflammation response score for prognostic prediction of breast cancer patients undergoing surgery[J].J Pers Med, 2021,11(5):413.
[5] ZOU H,LIU S H,YANG R,et al.Combination of neutrophil-to-lymphocyte ratio and red cell distribution width with serum tumor markers for the differential diagnosis of breast cancer and its association with pathological features and molecular types[J].Clin Breast Cancer,2022,22(4):e526-e535.
[6] GUO W,LU X,LIU Q,et al.Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17 079 individuals[J].Cancer Med,2019,8(9):4135-4148.
[7] LIU Y,HE M,WANG C,et al.Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: a meta-analysis[J].Medicine(Baltimore),2022,101(28):e29887.
[8] YIN Y,ZHANG Y,LI L,et al.Prognostic value of pretreatment lymphocyte-to-monocyte ratio and development of a nomogram in breast cancer patients[J].Front Oncol,2021,11:650980.
[9] KIM J H,SON N H,LEE J S,et al.Time-Sequencing of the neutrophil-to-lymphocyte ratio to predict prognosis of triple-negative breast cancer[J].Cancers(Basel),2021,13(14):3472.
[10] CULLINANE C,CREAVIN B,O'LEARY D P,et al.Can the neutrophil to lymphocyte ratio predict complete pathologic response to neoadjuvant breast cancer treatment? A systematic review and meta-analysis[J].Clin Breast Cancer,2020,20(6):e675-e681.
[11] ZHOU Q,DONG J,SUN Q,et al.Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis[J].BMJ Open,2021,11(9):e047957.
[12] CORBEAU I,JACOT W,GUIU S.Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review[J].Cancers(Basel),2020,12(4):958.
[13] DAN J,TAN J,HUANG J,et al.The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients[J].Breast Cancer,2020,27(5):982-988.
[14] POLLEY M C,LEON-FERRE R A,LEUNG S,et al.A clinical calculator to predict disease outcomes in women with triple-negative breast cancer[J].Breast Cancer Res Treat,2021,185(3):557-566.
[15] TANG L,SHU X,TU G.Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive,HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study[J].World J Surg Oncol,2022,20(1):27.
[16] ZHU J,JIAO D,ZHAO Y,et al.Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients[J].Sci Rep,2021,11(1):1350.
[17] YE P,DUAN H,ZHAO Z,et al.A Practical predictive model based on ultrasound imaging and clinical indices for estimation of response to neoadjuvant chemotherapy in patients with breast cancer[J].Cancer Manag Res,2021,13:7783-7793.
[18] TRUFFI M,PICCOTTI F,ALBASINI S,et al.Preoperative systemic inflammatory biomarkers are independent predictors of disease recurrence in ER+HER2- early breast cancer[J].Front Oncol,2021,11:773078.
[19] ZHENG Y,WU C,YAN H,et al.Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: a prognostic nomogram study[J].Clin Chim Acta,2020,506:110-121.
[20] KIM J Y,JUNG E J,KIM J M,et al.Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis[J].BMC Cancer,2020,20(1):1206.
[21] ORLANDINI L F,PIMENTEL F F,ANDRADE J M,et al.Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients[J].Braz J Med Biol Res,2021,54(10):e11409.
[22] TAKADA K,KASHIWAGI S,ASANO Y,et al.Prediction of sentinel lymph node metastasis using the platelet-to-lymphocyte ratio in T1 breast cancer[J].Anticancer Res,2020,40(4):2343-2349.
[23] YANG L,WANG H,MA J,et al.Association between the platelet to lymphocyte ratio,neutrophil to lymphocyte ratio and axillary lymph node metastasis in cT1N0 breast cancer patients[J].Am J Transl Res,2021,13(3):1854-1861.
[24] JIN X,WANG K,SHAO X,et al.Prognostic implications of the peripheral platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer patients[J].Gland Surg,2022,11(6):1057-1066.
[25] KAYTAZ TEKYOL K,GURLEYIK G,AKTAS A,et al.Pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: the relationship between inflammatory biomarkers and molecular subtypes[J].Cureus,2021,13(4):e14774.
[26] MA Y,ZHANG J,CHEN X.Lymphocyte-to-monocyte ratio is associated with the poor prognosis of breast cancer patients receiving neoadjuvant chemotherapy[J].Cancer Manag Res,2021,13:1571-1580.
[27] EREN T,KARACIN C,UCAR G,et al.Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients[J].Medicine(Baltimore),2020,99(22):e20346.
[28] LOU C,JIN F,ZHAO Q,et al.Correlation of serum NLR,PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer[J].Am J Transl Res,2022,14(5):3240-3246.
[29] HU Y,WANG S,DING N,et al.Platelet/lymphocyte ratio is superior to neutrophil/lymphocyte ratio as a predictor of chemotherapy response and disease-free survival in luminal b-like(HER2-) breast cancer[J].Clin Breast Cancer,2020,20(4):e403-e409.
[30] AL JARROUDI O,EL BAIRI K,ABDA N,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer[J].Biomark Med,2021,15(14):1289-1298.
[31] 徐良,张百红.淋巴细胞相关指标对乳腺癌预后作用的研究进展[J].医学研究生学报,2020,33(8):867-872.
[32] ZHANG Z,LIN Q,CHEN Y,et al.Prognostic evaluation of metastasis-related lymphocyte/monocyte ratio in stage Ⅰ-Ⅲ breast cancer receiving chemotherapy[J].Front Oncol,2022,11:782383.
[33] LI X,WANG J,FU J,et al.Prognostic significance of preoperative serum inflammation markers in patients with male breast cancer[J].Transl Cancer Res,2021,10(9):4002-4008.
[34] PENG Y,CHEN R,QU F,et al.Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients[J].Cancer Biol Ther,2020,21(2):189-196.
[35] SONG D,LI X,ZHANG X.Expression and prognostic value of ratios of platelet lymphocyte,neutrophil lymphocyte and lymphocyte monocyte in breast cancer patients[J].Am J Transl Res,2022,14(5):3233-3239.
[36] ZHAO J M,AN Q,SUN C N,et al.Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients[J].Breast Cancer,2021,28(2):298-306.
[37] HUANG Z N,LI Z X,YAO Z C,et al.Clinical prognostic evaluation of immunocytes in different molecular subtypes of breast cancer[J].J Cell Physiol,2019,234(11):20584-20602.
[38] RIMINI M,CASADEI-GARDINI A,RAVAIOLI A,et al.Could inflammatory indices and metabolic syndrome predict the risk of cancer development? Analysis from the Bagnacavallo Population Study[J].J Clin Med,2020,9(4):1177.
[39] ZHANG Y,SUN Y,ZHANG Q.Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis[J].Cancer Cell Int,2020,20:224.
[40] JI Y,WANG H.Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis[J].World J Surg Oncol,2020,18(1):197.
[41] PANG J,WANG S,LIAO L,et al.Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer[J].Journal of Central South University(Medical Science),2021,46(9):958-965.
[42] ZHU M,CHEN L,KONG X,et al.The systemic immune-inflammation index is an independent predictor of survival in breast cancer patients[J].Cancer Manag Res,2022,14:775-820.
[43] JIANG C,LU Y,ZHANG S,et al.Systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy[J].Biomed Res Int,2020,2020:7961568.
[44] HUA X,LONG Z Q,HUANG X,et al.The preoperative systemic inflammation response index(SIRI) independently predicts survival in postmenopausal women with breast cancer[J].Curr Probl Cancer,2020,44(4):100560.
[45] WANG L,ZHOU Y,XIA S,et al.Prognostic value of the systemic inflammation response index(SIRI) before and after surgery in operable breast cancer patients[J].Cancer Biomark,2020,28(4):537-547.
[46] DONG J,SUN Q,PAN Y,et al.Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy[J].BMC Cancer,2021,21(1):700.
[47] HE Q,LI J Y,REN Q L.Efficacy of neoadjuvant single or dual anti-HER-2 therapy combined with chemotherapy in patients with HER-2-Positive breast cancer: a single-center retrospective study[J].Asian Pac J Cancer Prev,2021,22(5):1467-1475.
[48] JIANG C,ZHANG S,QIAO K,et al.The pretreatment systemic inflammation response index as a useful prognostic factor is better than lymphocyte to monocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy[J].Clin Breast Cancer,2022,22(5):424-438.
[49] HUA X,DUAN F,ZHAI W,et al.A novel inflammatory-nutritional prognostic scoring system for patients with early-stage breast cancer[J].J Inflamm Res,2022,15:381-394. |
